tetano
Editor, Senior Moderator
Vaccine
. 2025 Jul 29:62:127556.
doi: 10.1016/j.vaccine.2025.127556. Online ahead of print. Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time
Hiam Chemaitelly[SUP] 1 [/SUP], Houssein H Ayoub[SUP] 2 [/SUP], Peter Coyle[SUP] 3 [/SUP], Patrick Tang[SUP] 4 [/SUP], Mohammad R Hasan[SUP] 5 [/SUP], Hadi M Yassine[SUP] 6 [/SUP], Asmaa A Al Thani[SUP] 6 [/SUP], Zaina Al-Kanaani[SUP] 7 [/SUP], Einas Al-Kuwari[SUP] 7 [/SUP], Andrew Jeremijenko[SUP] 7 [/SUP], Anvar Hassan Kaleeckal[SUP] 7 [/SUP], Ali Nizar Latif[SUP] 7 [/SUP], Riyazuddin Mohammad Shaik[SUP] 7 [/SUP], Hanan F Abdul-Rahim[SUP] 8 [/SUP], Gheyath K Nasrallah[SUP] 6 [/SUP], Mohamed Ghaith Al-Kuwari[SUP] 9 [/SUP], Adeel A Butt[SUP] 10 [/SUP], Hamad Eid Al-Romaihi[SUP] 11 [/SUP], Mohamed H Al-Thani[SUP] 11 [/SUP], Abdullatif Al-Khal[SUP] 7 [/SUP], Laith J Abu-Raddad[SUP] 12 [/SUP]
Affiliations
Background: Supply constraints during the coronavirus disease 2019 (COVID-19) pandemic led to vaccination strategies that prioritized first-dose coverage. To evaluate the merit of this approach, this study compared the development of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 following a single dose versus two doses across three widely used vaccine platforms.
Methods: National, matched, test-negative case-control analyses were conducted in Qatar between December 1, 2020, and December 18, 2021, to evaluate vaccine effectiveness. The one-dose analysis included 227,309 cases and 4,170,786 controls; the two-dose analysis included 234,314 cases and 6,445,858 controls.
Results: For BNT162b2, single-dose effectiveness against infection increased steadily from 9.9 % (95 % CI: 6.7-13.0 %) in the first two weeks post-vaccination to 71.5 % (95 % CI: 45.5-85.1 %) by month 3, closely approaching the 74.5 % (95 % CI: 72.9-76.0 %) effectiveness observed after the two-dose primary series. Similar trends were observed for mRNA-1273 and ChAdOx1 nCoV-19, with mRNA-1273 reaching two-dose levels of effectiveness as early as month 2. In contrast to the gradual buildup of protection against infection, single-dose effectiveness against severe, critical, or fatal COVID-19 increased rapidly for all three vaccines, exceeding 85 % by day 21 and closely matching the protection achieved after two doses.
Conclusion: A single COVID-19 vaccine dose provides rapid, strong protection against severe outcomes, supporting first-dose prioritization during supply constraints. The slower development of protection against infection highlights the second dose's role in accelerating the immune response. Antigen dose appears to influence the speed of protection buildup.
Keywords: BNT162b2; Case-control; ChAdOx1 nCoV-19; Immunity; Test-negative; mRNA-1273.
. 2025 Jul 29:62:127556.
doi: 10.1016/j.vaccine.2025.127556. Online ahead of print. Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time
Hiam Chemaitelly[SUP] 1 [/SUP], Houssein H Ayoub[SUP] 2 [/SUP], Peter Coyle[SUP] 3 [/SUP], Patrick Tang[SUP] 4 [/SUP], Mohammad R Hasan[SUP] 5 [/SUP], Hadi M Yassine[SUP] 6 [/SUP], Asmaa A Al Thani[SUP] 6 [/SUP], Zaina Al-Kanaani[SUP] 7 [/SUP], Einas Al-Kuwari[SUP] 7 [/SUP], Andrew Jeremijenko[SUP] 7 [/SUP], Anvar Hassan Kaleeckal[SUP] 7 [/SUP], Ali Nizar Latif[SUP] 7 [/SUP], Riyazuddin Mohammad Shaik[SUP] 7 [/SUP], Hanan F Abdul-Rahim[SUP] 8 [/SUP], Gheyath K Nasrallah[SUP] 6 [/SUP], Mohamed Ghaith Al-Kuwari[SUP] 9 [/SUP], Adeel A Butt[SUP] 10 [/SUP], Hamad Eid Al-Romaihi[SUP] 11 [/SUP], Mohamed H Al-Thani[SUP] 11 [/SUP], Abdullatif Al-Khal[SUP] 7 [/SUP], Laith J Abu-Raddad[SUP] 12 [/SUP]
Affiliations
- PMID: 40738001
- DOI: 10.1016/j.vaccine.2025.127556
Background: Supply constraints during the coronavirus disease 2019 (COVID-19) pandemic led to vaccination strategies that prioritized first-dose coverage. To evaluate the merit of this approach, this study compared the development of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 following a single dose versus two doses across three widely used vaccine platforms.
Methods: National, matched, test-negative case-control analyses were conducted in Qatar between December 1, 2020, and December 18, 2021, to evaluate vaccine effectiveness. The one-dose analysis included 227,309 cases and 4,170,786 controls; the two-dose analysis included 234,314 cases and 6,445,858 controls.
Results: For BNT162b2, single-dose effectiveness against infection increased steadily from 9.9 % (95 % CI: 6.7-13.0 %) in the first two weeks post-vaccination to 71.5 % (95 % CI: 45.5-85.1 %) by month 3, closely approaching the 74.5 % (95 % CI: 72.9-76.0 %) effectiveness observed after the two-dose primary series. Similar trends were observed for mRNA-1273 and ChAdOx1 nCoV-19, with mRNA-1273 reaching two-dose levels of effectiveness as early as month 2. In contrast to the gradual buildup of protection against infection, single-dose effectiveness against severe, critical, or fatal COVID-19 increased rapidly for all three vaccines, exceeding 85 % by day 21 and closely matching the protection achieved after two doses.
Conclusion: A single COVID-19 vaccine dose provides rapid, strong protection against severe outcomes, supporting first-dose prioritization during supply constraints. The slower development of protection against infection highlights the second dose's role in accelerating the immune response. Antigen dose appears to influence the speed of protection buildup.
Keywords: BNT162b2; Case-control; ChAdOx1 nCoV-19; Immunity; Test-negative; mRNA-1273.